|
|||||
|
|
||||||
© 2003 American Society for Clinical Oncology
Small-Cell Cancers, and an Unusual Reaction to ChemotherapyCASE 4. FLUOROURACIL-RELATED SMALL BOWEL VASCULITISGeisinger Medical Center, Danville, PA Fluorouracil (FU) is one of the most commonly used chemotherapeutic agents in clinical oncology practice, alone or in differentcombinations. In colorectal cancer the addition of leucovorin (LV) to FU resulted in improved patient survival, improved objectivetumor response, and better quality of life.1 We report a case of ischemic small-bowel injury in a patient who received adjuvantchemotherapy with oxaliplatin (OP), FU, and LV and was found to have angiographic evidence of vasculitis in the superiormesenteric artery (SMA) territory. This will add to the series of patients reported with FU-related or FU-induced vascular injury tothe small bowel.2
A 73-year-old male underwent a left hemicolectomy for stage III colon cancer. He was enrolled in an adjuvant chemotherapyresearch protocol consisting of FU 500 mg/m2 intravenous (IV) weekly boluses, each administered during 1 hour; LV 500 mg/m2IV weekly infusions, each administered during 2 hours; and OP 85 mg/m2 IV infusions every 2 weeks for 6 weeks, followed by 2weeks of rest. After the third cycle of FU, LV, and OP, he presented with weakness, diarrhea, abdominal cramps, and poor appetite.His abdomen was distended and he had heme-positive stools. Stool cultures and Clostridium difficile toxin antigen were negative.He was not neutropenic. Colonoscopy revealed dusky edematous changes in the ascending colon and focal ulceration with patchysubmucosal hemorrhages in the distal ileum (Figs 1
We present a case of ischemic bowel injury in the SMA territory in a patient who received adjuvant FU-based therapy for stageIII colon cancer. Vascular effects of FU have been reported mainly in patients who developed cardiotoxicity.3 The relationshipbetween the type of administration bolus versus continuous infusion is not clear, although the majority of patients who developedcardiotoxicity received the drug continuously.35 A series of patients with resected adenocarcinoma of colon who were treated with FU and LV and developed severe erosions andsuperficial ulcerations in the ileum has been described.2 These patients were successfully rechallenged with a 20% reduction of FUdose without further toxicities. The mechanisms involved are thought to be multifactorial, including alteration of local mucosal bloodflow4,6 and thrombogenic7 and vasospastic3,8 effects of FU on the vascular epithelium. Indeed, Mosseri et al8 demonstrated in vitrothat FU causes direct endothelial-independent vasoconstriction related to activation of protein kinase C.
Our patient had superficial erosions and ulcerations in the ileum (Fig 3
REFERENCES
Poon M, OConnel MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:19671972, 1991 Fata F, Ron IG, Kemeny N, et al: 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86:11291134, 1999[CrossRef][Medline]
Gradishar WJ, Vokes EE: 5-Fluorouracil cardiotoxicity: A critical review. Ann Oncol 1:409414, 1990 Narsete Th, Ansfield F, Wirtanen G, et al: Gastric ulceration in patients receiving intrahepatic infusion of 5-fluorouracil. Ann Surg 186:734737, 1977[Medline] Suda K, Seki T, Kano Y, et al: Continuous 5-fluorouracil infusion acute causing gastric mucosal lesions. Endoscopy25:426427, 1993[Medline] Kakinuma S, Ohwada S: Gastric mucosal blood flow and gastric secretion following intravenous administration of 5-fluorouracil in rats. Cancer Chemother Pharmacol 39:357360, 1997[CrossRef][Medline] Kuzel T, Esparaz B, Green D, et al: Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65:885889, 1990[CrossRef][Medline]
Mosseri M, Fingert HJ, Vartikosski L, et al: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase c-mediated vasoconstriction of vascular smooth muscle. Cancer Res 53:30283033, 1993
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|